These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30810071)

  • 1. PET is necessary to make the next step forward in understanding MS pathophysiology - Yes.
    Bodini B; Stankoff B
    Mult Scler; 2019 Jul; 25(8):1086-1087. PubMed ID: 30810071
    [No Abstract]   [Full Text] [Related]  

  • 2. PET is necessary to make the next step forward in understanding MS pathophysiology - No.
    Preziosa P; Rocca MA; Filippi M
    Mult Scler; 2019 Jul; 25(8):1088-1090. PubMed ID: 30810073
    [No Abstract]   [Full Text] [Related]  

  • 3. PET is necessary to make the next step forward in understanding MS pathophysiology - Commentary.
    Kang Y; Gauthier SA
    Mult Scler; 2019 Jul; 25(8):1090-1091. PubMed ID: 30810087
    [No Abstract]   [Full Text] [Related]  

  • 4. Ultra-high-field (7.0 Tesla and above) MRI is now necessary to make the next step forward in understanding MS pathophysiology - YES.
    Bagnato F; Gore JC
    Mult Scler; 2017 Mar; 23(3):372-373. PubMed ID: 28260420
    [No Abstract]   [Full Text] [Related]  

  • 5. Positron emission tomography imaging in evaluation of MS pathology in vivo.
    Högel H; Rissanen E; Vuorimaa A; Airas L
    Mult Scler; 2018 Oct; 24(11):1399-1412. PubMed ID: 30091657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GMP--three letters with many interpretations. Protection of patients or killing the clinical and research applications of PET?
    Långström B; Hartvig P
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):693-4. PubMed ID: 18157532
    [No Abstract]   [Full Text] [Related]  

  • 7. CGMP for PET drugs: important steps to take now.
    Vanbrocklin H; Schwarz S
    J Nucl Med; 2010 Dec; 51(12):17N. PubMed ID: 21098789
    [No Abstract]   [Full Text] [Related]  

  • 8. Final PET CGMP regulation.
    Breslow K; Schwarz SW
    J Nucl Med; 2010 Mar; 51(3):15N-6N. PubMed ID: 20197439
    [No Abstract]   [Full Text] [Related]  

  • 9. The future of USP monographs for PET drugs.
    Schwarz S; Norenberg J; Berridge M; Dragotakes S; Hung J; Link J; Mason NS; Mattmuller S; Nickel RA; Packard A; Paolino J; Petry N; Ponto J; Quinton TM; Seifert KL; Swanson D; Weiner RE; Zigler S
    J Nucl Med; 2013 Mar; 54(3):472-5. PubMed ID: 23264689
    [No Abstract]   [Full Text] [Related]  

  • 10. Positron emission tomography in multiple sclerosis - straight to the target.
    Bodini B; Tonietto M; Airas L; Stankoff B
    Nat Rev Neurol; 2021 Nov; 17(11):663-675. PubMed ID: 34545219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-THK5351 PET Can Identify Astrogliosis in Multiple Sclerosis Plaques.
    Ishibashi K; Miura Y; Hirata K; Toyohara J; Ishii K
    Clin Nucl Med; 2020 Feb; 45(2):e98-e100. PubMed ID: 31348091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current good manufacturing practice for positron emission tomography drugs.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Dec; 74(236):65409-36. PubMed ID: 20169678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of multiple sclerosis with homonymous hemianopia examined by positron emission tomography.
    Murai H; Kiyosawa M; Suzuki Y; Mizoguchi S; Ishii K; Ishikawa K; Akashi T
    Jpn J Ophthalmol; 2004; 48(6):591-3. PubMed ID: 15592787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA cGMP requirements for PET drugs.
    Norenberg JP; Schwarz S; VanBrocklin H
    J Nucl Med; 2011 May; 52(5):16N. PubMed ID: 21536923
    [No Abstract]   [Full Text] [Related]  

  • 15. Current good manufacturing practices for PET drug products in the United States.
    Swanson D; Graham M; Heinonen TM; Libby P; Mills GQ
    J Nucl Med; 2009 Aug; 50(8):26N-8N. PubMed ID: 19652213
    [No Abstract]   [Full Text] [Related]  

  • 16. PET in multiple sclerosis.
    Niccolini F; Su P; Politis M
    Clin Nucl Med; 2015 Jan; 40(1):e46-52. PubMed ID: 24561681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is now current good manufacturing practice for PET drugs?
    Harolds J
    Clin Nucl Med; 2010 May; 35(5):329. PubMed ID: 20395704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Capabilities of positron emission tomography to study mecha-nisms of multiple sclerosis: own data and literature].
    Stolyarov ID; Petrov AM; Shkilnyuk GG; Kataeva GV; Prakhova LN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(2 Pt 2):27-31. PubMed ID: 27070358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT in tumefactive multiple sclerosis.
    Maffione AM; Rampin L; Grassetto G; L'Erario R; Colletti PM; Rubello D
    Clin Nucl Med; 2014 Aug; 39(8):750-1. PubMed ID: 24686217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations in clinical PET/CT operations: results of an international survey of active PET/CT users.
    Beyer T; Czernin J; Freudenberg LS
    J Nucl Med; 2011 Feb; 52(2):303-10. PubMed ID: 21233186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.